cbdMD receives NYSE American acceptance of compliance plan; faces Dec 5, 2025 deadline

cbdMD, Inc.

Stockholders' deficit of $3.1M as of March 31, 2024; non-compliance with $4M equity requirement.
Plan period through December 5, 2025; quarterly reviews to monitor progress.
If plan fails, NYSE American may initiate delisting proceedings; common and preferred shares remain listed during period.
CEO notes plan acceptance is step to address capital structure and re-engage preferred shareholders on accrued dividend.
Prior non-compliance notice received June 5, 2024 under Section 1003(a)(ii) for losses in three of four recent fiscal years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.